paediatrics Brussels 17

Group III Orbital RMS

Protocol

Dose (Gy)

Chemotherapy Timing of RT (week)

5-year local failure rate (%)

5-year failure-free survival (%)

IRS-III (n = 71) IRS-IV (n = 49)

41.4 – 50.4 50.4- 59.4

VA

2 or 6

16

79

VAC(26.4g/m 2 )/ VAI/VIE

9

2

94

D9602

45 VA

13

14

86

45 VAC(4.8g/m 2 )

ARST0331

13

13

87

CR (n = 15)

0

100

16

84

PR/SD (n =38)

Ermoian RP et al. Pediatr Blood Cancer 2017; 64:e26540